Abstract:Key PointsCell-free DNA (cfDNA) is released predominantly by cell death into the bloodstream, although active secretion may have a role. Since the discovery of fetal cfDNA in the maternal circulation, cfDNA analysis has been rapidly implemented in clinical practice for noninvasive prenatal testing.Mutations were first detected in cfDNA more than two decades ago, and interest in circulating tumour DNA (ctDNA) as a noninvasive cancer diagnostic has increased considerably with the development of molecular methods that permit the sensitive detection and monitoring of multiple classes of mutation.ctDNA may have utility at almost every stage of the management of patients with cancer, including diagnosis, minimally invasive molecular profiling, treatment monitoring, the detection of residual disease and the identification of resistance mutations. ctDNA analysis may be broadly considered as a tool both for quantitative analysis of disease burden and for genomic analysis.The identification of ctDNA in individuals before a cancer diagnosis, and in presymptomatic individuals, suggests the possibility of ctDNA analysis as a tool for earlier detection and screening. Noninvasive cancer classification or subtyping has also emerged as a possibility, although for early detection, both technical and biological factors introduce challenges to the detection of mutant DNA in plasma and its interpretation.Monitoring multiple mutations in parallel can enhance the sensitivity of ctDNA detection, can be used to assess the clonal evolution of patients' disease and may identify resistance mutations before clinical progression is observed.ctDNA analysis is beginning to transition from the research setting into the clinic. The US Food and Drug Administration and the European Medicines Agency have approved ctDNA tests for specific indications in the absence of evaluable tumour tissue. Analysis of gene panels in plasma has now become available as a potential clinical tool. Large studies are under way to establish the overall performance and clinical utility of such assays when a tumour biopsy is not available for analysis.Potential applications of ctDNA have been demonstrated by a number of proof-of-principle studies. Prospective clinical trials are beginning to assess the clinical utility of ctDNA analysis for molecular profiling and disease monitoring. The increasing acceptance of ctDNA is enabling the field to move from exploratory ctDNA studies towards clinical trials in which ctDNA guides decision-making.In order to fully exploit the potential utility of liquid biopsies, it is essential that the biology of cfDNA and ctDNA is explored further. The mechanisms of release and degradation, and the factors that affect the representation of ctDNA in plasma, are poorly understood. The nature of ctDNA will be clarified through both large, well-annotated clinical studies and in vivo studies in which variables can be controlled.

[Practical Stability of Whole-Genome Bisulfite Sequencing Using Plasma Cell-Free DNA].

Evaluating DNA recovery efficiency following bisulphite modification from plasma samples submitted for cell-free DNA methylation analysis

Comprehensive Evaluation of the Impact of Whole-Genome Bisulfite Sequencing (WGBS) on the Fragmentomic Characteristics of Plasma Cell-Free DNA

A review on the impact of single-stranded library preparation on plasma cell-free diversity for cancer detection

LiBis: an ultrasensitive alignment augmentation for low-input bisulfite sequencing

Systematic Evaluation of Cell Type Deconvolution Methods for Plasma Cell-free DNA

FinaleMe: Predicting DNA methylation by the fragmentation patterns of plasma cell-free DNA

Baseline mutation profiling of circulating cell-free DNA from healthy individuals to improve the detection accuracy of circulating tumor DNA in cancers.

Evaluation of commercial kits for isolation and bisulfite conversion of circulating cell-free tumor DNA from blood

Challenges and Prospects of Cell-Free DNA in Precision Oncology

Whole-genome bisulfite sequencing analysis of circulating tumour DNA for the detection and molecular classification of cancer

Liquid Biopsies: DNA Methylation Analyses in Circulating Cell-Free DNA

Abstract 5109: Development of cfDNA reference standards for methylation-sequencing tests

Cell-Free DNA Fragmentomics: the Novel Promising Biomarker

Liquid footprinting: A novel approach for DNA footprinting using short double-stranded cell-free DNA from plasma

Development of a Method to Implement Whole-Genome Bisulfite Sequencing of cfDNA from Cancer Patients and a Mouse Tumor Model

Liquid biopsies come of age: towards implementation of circulating tumour DNA

A Practical Approach for Targeting Structural Variants Genome-wide in Plasma Cell-free DNA

Comprehensive DNA Methylation Analysis of Tissue of Origin of Plasma Cell-Free DNA by Methylated CpG Tandem Amplification and Sequencing (Mcta-Seq)

Whole genome deep sequencing analysis of cell-free DNA in samples with low tumour content